91 related articles for article (PubMed ID: 3970557)
21. [Effect of C-reactive protein on natural killer activity].
Shibuya M; Saijo N; Shimizu E; Taniguchi T; Takizawa T; Fujioka H; Hoshi A
Gan To Kagaku Ryoho; 1983 Nov; 10(11):2341-6. PubMed ID: 6639096
[TBL] [Abstract][Full Text] [Related]
22. [The effect of sera of breast cancer patients on NK cell activity].
Konjević G; Spuzić I
Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
[TBL] [Abstract][Full Text] [Related]
23. [Autologous tumor specific immunotherapy of refractory cancers with ex vivo-generated T cells stimulated by autologous tumor cell].
Toh U; Yamana H; Kido K; Mine T; Fujii T; Horiuchi H; Sasatomi T; Ishibashi N; Yutani S; Fujita H; Shirouzu K
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1566-70. PubMed ID: 14619465
[TBL] [Abstract][Full Text] [Related]
24. [Intracavitary administration of recombinant interferon in cancer patients with malignant effusions].
Takashima S; Saeki T; Saeki H; Tanada M; Takiyama W; Kimura T; Moriwaki S
Gan No Rinsho; 1986 Sep; 32(11):1451-7. PubMed ID: 3773273
[TBL] [Abstract][Full Text] [Related]
25. In vivo priming effects of interferon-beta ser on NK activity of peripheral blood mononuclear cells in cancer patients.
Fujimiya Y; Wagner RJ; Groveman S; Sielaff K; Kohsaka T; Nakayama M
Ther Immunol; 1995 Feb; 2(1):15-22. PubMed ID: 7553067
[TBL] [Abstract][Full Text] [Related]
26. Systemic administration of human leukocyte interferon to melanoma patients. III. Increased helper:suppressor cell ratios in melanoma patients during interferon treatment.
Karavodin LM; Golub SH
Nat Immun Cell Growth Regul; 1983-1984; 3(4):193-202. PubMed ID: 6241293
[TBL] [Abstract][Full Text] [Related]
27. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial.
Krause SW; Gastpar R; Andreesen R; Gross C; Ullrich H; Thonigs G; Pfister K; Multhoff G
Clin Cancer Res; 2004 Jun; 10(11):3699-707. PubMed ID: 15173076
[TBL] [Abstract][Full Text] [Related]
28. Cytotoxicity tests against cultured human lung cancer cells with autologous lymphocytes activated in vitro by mitomycin C-treated tumor monolayers in the presence of T-cell growth factor.
Kimura H; Yamaguchi Y; Kadoyama C; Sato N; Fujisawa T
Jpn J Clin Oncol; 1983 Mar; 13(1):3-13. PubMed ID: 6300483
[TBL] [Abstract][Full Text] [Related]
29. Beneficial effects of interleukin-2 on natural killer activity in lung cancer patients.
Ito M; Suzuki H; Yamashita N; Sugiyama E; Maruyama M; Sato M; Iwata M; Yano S
Anticancer Res; 1984; 4(6):375-8. PubMed ID: 6097158
[TBL] [Abstract][Full Text] [Related]
30. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon.
Lotzová E; Savary CA; Quesada JR; Gutterman JU; Hersh EM
J Natl Cancer Inst; 1983 Nov; 71(5):903-10. PubMed ID: 6580490
[TBL] [Abstract][Full Text] [Related]
31. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.
Schmidt-Wolf IG; Finke S; Trojaneck B; Denkena A; Lefterova P; Schwella N; Heuft HG; Prange G; Korte M; Takeya M; Dorbic T; Neubauer A; Wittig B; Huhn D
Br J Cancer; 1999 Nov; 81(6):1009-16. PubMed ID: 10576658
[TBL] [Abstract][Full Text] [Related]
32. [Immunological effect of recombinant interferon-gamma in renal cell carcinoma].
Kawata N; Ono M; Endo M; Ichinose T; Hamada T; Hirano D; Fuse T; Takimoto Y
Hinyokika Kiyo; 1993 Jun; 39(6):511-5. PubMed ID: 8337976
[TBL] [Abstract][Full Text] [Related]
33. Natural killer cells and interferon responses in patients with systemic lupus erythematosus.
Tsokos GC; Rook AH; Djeu JY; Balow JE
Clin Exp Immunol; 1982 Nov; 50(2):239-45. PubMed ID: 6817954
[TBL] [Abstract][Full Text] [Related]
34. Basic and interferon-augmented natural killer (NK) cell activity in psoriasis.
Jansén CT; Viander M
Acta Derm Venereol; 1983; 63(5):384-7. PubMed ID: 6197835
[TBL] [Abstract][Full Text] [Related]
35. [Influence of extirpative surgery on the natural killer cell activity in peripheral blood in cancer patients].
Wang H
Zhonghua Wai Ke Za Zhi; 1990 Oct; 28(10):622-4, 638. PubMed ID: 2086059
[TBL] [Abstract][Full Text] [Related]
36. Immunological effects of recombinant interferon-alpha 2 in cancer patients.
Hengst JC; Kempf RA; Kan-Mitchell J; Pham AT; Grunberg SM; Kortes VL; Mitchell MS
J Biol Response Mod; 1983; 2(6):516-27. PubMed ID: 6663321
[TBL] [Abstract][Full Text] [Related]
37. Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons.
Brunda MJ; Rosenbaum D
Cancer Res; 1984 Feb; 44(2):597-601. PubMed ID: 6692364
[TBL] [Abstract][Full Text] [Related]
38. Effect of lymphoblastoid interferon on lymphocyte subsets in cancer patients.
Silver HK; Connors JM; Karim KA; Kong S; Spinelli JJ; de Jong G; McLean DM; Salinas FA
J Biol Response Mod; 1983; 2(5):428-40. PubMed ID: 6644347
[TBL] [Abstract][Full Text] [Related]
39. Augmentation of natural killer cell activity after arterial embolization of renal carcinomas.
Bakke A; Göthlin JH; Haukaas SA; Kalland T
Cancer Res; 1982 Sep; 42(9):3880-3. PubMed ID: 7105048
[TBL] [Abstract][Full Text] [Related]
40. The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients.
Konishi J; Yamazaki K; Yokouchi H; Shinagawa N; Iwabuchi K; Nishimura M
Hum Immunol; 2004 Nov; 65(11):1377-88. PubMed ID: 15556688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
